 | Up a level |
Rottenburger, Christof; Hentschel, Michael; Fürstner, Markus; McDougall, Lisa; Kottoros, Danijela; Kaul, Felix; Mansi, Rosalba; Fani, Melpomeni; Vija, A Hans; Schibli, Roger; Geistlich, Susanne; Behe, Martin; Christ, Emanuel R; Wild, Damian (2024). In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study. EJNMMI research, 14(37) Springer 10.1186/s13550-024-01101-w
Rottenburger, Christof; Nicolas, Guillaume P; McDougall, Lisa; Kaul, Felix; Cachovan, Michal; Vija, A Hans; Schibli, Roger; Geistlich, Susanne; Schumann, Anne; Rau, Tilman; Glatz, Kathrin; Behe, Martin; Christ, Emanuel R; Wild, Damian (2020). Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma - Results of the Lumed Phase 0a Study. Journal of nuclear medicine, 61(4), pp. 520-526. Society of Nuclear Medicine 10.2967/jnumed.119.233031
Sah, Bert-Ram; Sommerauer, Michael; Mu, Linjing; Gonzalez, Gloria Pla; Geistlich, Susanne; Treyer, Valerie; Schibli, Roger; Buck, Alfred; Warnock, Geoffrey; Ametamey, Simon M (2019). Radiation dosimetry of [F]-PSS232-a PET radioligand for imaging mGlu5 receptors in humans. EJNMMI research, 9(1), p. 56. Springer 10.1186/s13550-019-0522-9
